The Experts below are selected from a list of 654 Experts worldwide ranked by ideXlab platform

Boni E. Elewski - One of the best experts on this subject based on the ideXlab platform.

  • Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002
    Journal of the American Academy of Dermatology, 2004
    Co-Authors: K. Wade Foster, Mahmoud A. Ghannoum, Boni E. Elewski
    Abstract:

    Abstract Background Cutaneous fungal infections are common in the United States, and causative organisms include dermatophytes, yeasts, and nondermatophyte molds. These organisms are in constant competition for their particular environmental niche, often resulting in the emergence of one or more predominant pathogens and displacement of other less competitive species. Changes in the incidence of fungal pathogens can be followed from laboratory culture results of infected cutaneous tissues over time. These data can be used to ascertain past and present trends in incidence, predict increases in antifungal resistance and the adequacy of our current pharmacologic repertoire, and provide insight into future developments. Objective This study identifies epidemiologic trends and the predominant organisms causing superficial fungal infections in the United States. Methods A total of 15,381 specimens were collected from clinically suspected Tinea corporis, Tinea cruris, Tinea capitis, Tinea faciei, Tinea pedis, Tinea manuum, and finger and toe onychomycosis from 1999 through 2002. Specimens were submitted to the Center for Medical Mycology in Cleveland, Ohio, for fungal culture and identification, and the incidence of each species was calculated. Results Dermatophytes remain the most commonly isolated fungal organisms except from clinically suspected finger onychomycosis, in which case Candida species comprise >70% of isolates. Trichophyton rubrum remains the most prevalent fungal pathogen, and increased incidence of this species was observed in finger and toe onychomycosis, Tinea corporis and Tinea cruris, Tinea manuum, and Tinea pedis. As the causal agent of Tinea capitis, T tonsurans continues to increase in incidence, achieving near exclusionary proportions in the United States. Conclusion Consideration of the current epidemiologic trends in the incidence of cutaneous fungal pathogens is of key importance to investigational efforts, diagnosis, and treatment.

  • Tinea corporis Tinea cruris Tinea nigra and piedra
    Dermatologic Clinics, 2003
    Co-Authors: Maria M Chaudhry, Boni E. Elewski
    Abstract:

    Tinea infections are among the most commondermatologic conditions throughout the world. Skinringworm infections, such as Tinea corporis and Tineacruris, are primarily caused by the dermatophytesTrichophyton rubrum, Trichophyton mentagrophytes,and Microsporum canis. Tinea nigra is an infection ofthe palms or soles, which may be associated withtravel to endemic regions (eg, Southeast UnitedStates and Central America). Black or white nodulesfound along the shaft of the hair may be infectionswith Piedraia hortae,orTrichosporon species, betterknown as ‘‘black piedra’’ or ‘‘white piedra.’’ Toavoid a misdiagnosis, identification of dermatophyteinfections requires both a fungal culture on Sabour-aud’s agar media, and a mycologic examination,consisting of a 10% to 15% KOH preparation, fromskin scrapings. Topical antifungals may be sufficientfor treatment of Tinea corporis and cruris and Tineanigra, and the shaving of hair infected by piedra mayalso be beneficial. Systemic therapy, however, maybe required when the infected areas are large, mac-erated with a secondary infection, or in immunocom-promised individuals. Preventative measures of Tineainfections include practicing good personal hygiene;keeping the skin dry and cool at all times; andavoiding sharing towels, clothing, or hair accessorieswith infected individuals.Tinea corporis and crurisDefinitionTinea corporis and Tinea cruris are superficialdermatophyte infections, commonly known as ‘‘ring-worm.’’ Tinea corporis includes all superficial der-matophyte infections of the glabrous skin, excludingthe scalp, beard, face, hands, feet, and groin. Tineacruris includes infections of the genitalia, pubic area,perineal skin, and perianal skin.Etiology and epidemiologyTinea corporis and Tinea cruris may be caused byany of the dermatophytes making up the generaTrichophyton, Microsporum,andEpidermophyton[1]. Both conditions are common throughout theworld, with men being affected by Tinea cruris morefrequently than women. The causative organism caninvade both the stratum corneum and the terminalhair of the affected areas [2]. Once infected, scalesmay be transmitted through direct contact betweenindividuals, or indirectly through contact with objectsthat carry the infected scales [3]. This transfer ofinfection is thought to occur through arthroconidiathat are shed by the infected host in skin scales [4].Autoinfection by other dermatophytes elsewhere inthe body, especially the foot to the groin, may also bea method of contracting a Tinea infection [5].Children are frequently infected with M canis,another causative organism of Tinea corporis, espe-cially those exposed to infected animals, such as

  • Tinea corporis, Tinea cruris, Tinea nigra, and piedra
    Dermatologic clinics, 2003
    Co-Authors: Maria M Chaudhry, Boni E. Elewski
    Abstract:

    Tinea infections are among the most common dermatologic conditions throughout the world. To avoid a misdiagnosis, identification of dermatophyte infections requires both a fungal culture on Sabouraud's agar media, and a light microscopic mycologic examination from skin scrapings. Topical antifungals may be sufficient for treatment of Tinea corporis and cruris and Tinea nigra, and the shaving of hair infected by piedra may also be beneficial. Systemic therapy, however, may be required when the infected areas are large, macerated with a secondary infection, or in immunocompromised individuals. Preventative measures of Tinea infections include practicing good personal hygiene; keeping the skin dry and cool at all times; and avoiding sharing towels, clothing, or hair accessories with infected individuals.

  • efficacy and safety of terbinafine 1 solution in the treatment of interdigital Tinea pedis and Tinea corporis or Tinea cruris
    Cutis, 2001
    Co-Authors: Mark Lebwohl, Drore Eisen, Boni E. Elewski, Ronald C Savin
    Abstract:

    : Two randomized, double-blind, vehicle-controlled, multicenter studies assessed the efficacy and safety of a new terbinafine 1% solution for the treatment of interdigital Tinea pedis and Tinea corporis or Tinea cruris (Tinea corporis/cruris). Patients with interdigital Tinea pedis applied terbinafine 1% solution or vehicle twice daily for 1 week with 7 weeks of follow-up (N = 153), and patients with Tinea corporis/cruris applied terbinafine 1% solution or vehicle once daily for 1 week with 3 weeks of follow-up (N = 66). Efficacy was assessed mycologically and clinically at the end of treatment and throughout follow-up. In the Tinea pedis study, 66% of patients were effectively treated with terbinafine compared with 4% of the group treated by vehicle (P < .001; Mantel-Haenszel test). In the Tinea corporis/cruris study, treatment was effective in 65% of the terbinafine group compared with 8% of the vehicle group (P < .001). There were no significant differences in the frequency of cutaneous adverse events between the 2 groups in either study. We conclude that one week of therapy with terbinafine 1% solution is highly effective, superior to vehicle, and safe for use in superficial fungal infections.

  • a u s epidemiologic survey of superficial fungal diseases
    Journal of The American Academy of Dermatology, 1996
    Co-Authors: Maggi E Kemna, Boni E. Elewski
    Abstract:

    Abstract Background: Large-scale studies performed outside the United States have demonstrated that most cases of onychomycosis and Tinea pedis are caused by dermatophytes, primarily Trichophyton rubrum . However, other studies have suggested that yeasts and nondermatophytic molds may play a role, particularly in onychomycosis. Objective: This study was undertaken to determine the epidemiology of superficial fungal infections in a U.S. population. Methods: Fungal cultures were performed on patients with clinically suspected Tinea cruris, Tinea corporis, Tinea capitis, Tinea pedis, and onychomycosis. Results: Dermatophytes were the most commonly isolated fungi in each type of superficial fungal disease studied. T. rubrum was the most commonly isolated dermatophyte species, although Trichophyton tonsurans was more common in Tinea capitis and equally common in Tinea corporis/Tinea cruris. In Tinea pedis and onychomycosis, dermatophytes appeared in approximately 95% and 82% of isolates, respectively. Candida albicans and nondermatophyte molds played only a minor role in onychomycosis; C. albicans was isolated in 7% of nail cultures and nondermatophytic molds were isolated in 11%. Conclusion: These results are in general agreement with other major epidemiologic studies performed outside the United States. Dermatophyte fungi cause most superficial fungal infections.

Magdy Elgohary - One of the best experts on this subject based on the ideXlab platform.

  • evidence based topical treatments for Tinea cruris and Tinea corporis a summary of a cochrane systematic review
    British Journal of Dermatology, 2015
    Co-Authors: E J Van Zuuren, Zbys Fedorowicz, Magdy Elgohary
    Abstract:

    Tinea cruris and Tinea corporis are common fungal infections. Most can be treated with a variety of topical antifungals. This review aimed to assess the evidence for the effectiveness and safety of topical treatments for Tinea cruris and Tinea corporis. Searches included the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library, Medline, Embase, LILACS and ongoing trials registries (August 2013). One hundred and twenty-nine randomized controlled trials (RCTs) with 18 086 participants evaluated a range of interventions - mostly azoles. Pooling of data for several outcomes was only possible for two individual treatments. In five studies, terbinafine showed a statistically significant higher clinical cure rate compared with placebo [risk ratio (RR) 4·51, 95% confidence interval (CI) 3·10-6·56]. Data for mycological cure could not be pooled owing to substantial heterogeneity. Across three studies, mycological cure rates favoured naftifine (1%) compared with placebo (RR 2·38, 95% CI 1·80-3·14) but the quality of the evidence was low. Combinations of azoles with corticosteroids were slightly more effective than azoles for clinical cure, but there was no statistically significant difference with regard to mycological cure. Sixty-five studies were assessed as 'unclear' and 64 as being at 'high risk' of bias; many were over 20 years old, and most were poorly designed and inadequately reported. Although most active interventions showed sufficient therapeutic effect, this review highlights the need for further, high-quality, adequately powered RCTs to evaluate the effects of these interventions, which can ultimately provide reliable evidence to inform clinical decision making.

  • evidence based topical treatments for Tinea cruris and Tinea corporis a summary of a cochrane systematic review
    British Journal of Dermatology, 2015
    Co-Authors: Esther J Van Zuuren, Zbys Fedorowicz, Magdy Elgohary
    Abstract:

    Tinea cruris and Tinea corporis are common fungal infections seen by both general practitioners and dermatologists. Most of these can be treated with a variety of topical antifungals. This review aimed to assess the evidence for the effectiveness and safety of topical treatments for Tinea cruris and Tinea corporis. Searches included: Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library, MEDLINE, EMBASE, LILACS, and ongoing trials registries (August 2013). 129 randomised controlled trials (RCTs) with 18,086 participants evaluated a range of interventions; mostly azoles. Pooling of data for several outcomes was only possible for two individual treatments. Terbinafine in 5 studies showed a statistically significant higher clinical cure rate compared to placebo (RR 4.51, 95% CI 3.10 to 6.56). Data for mycological cure could not be pooled due to substantial heterogeneity. Mycological cure rates favoured naftifine (1%) compared to placebo across three studies (RR 2.38, 95% CI 1.80 to 3.14) but the quality of the evidence was graded low. Combinations of azoles with corticosteroids were slightly more effective than azoles for clinical cure, but there was no statistically significant difference with regard to mycological cure. 65 studies were assessed at ‘unclear’ and 64 at ‘high risk’ of bias; many were over 20 years old and most were poorly designed and inadequately reported. Although most active interventions showed sufficient therapeutic effect, this review highlights the need for further, high quality, adequately powered RCTs to evaluate the effects of these interventions which can ultimately provide reliable evidence to inform clinical decision making.

  • topical antifungal treatments for Tinea cruris and Tinea corporis
    Cochrane Database of Systematic Reviews, 2014
    Co-Authors: Magdy Elgohary, Hana Burgess, Liz Doney, Beth Stuart, Michael Moore, Esther J Van Zuuren, Zbys Fedorowicz, Paul Little
    Abstract:

    Background Tinea infections are fungal infections of the skin caused by dermatophytes. It is estimated that 10% to 20% of the world population is affected by fungal skin infections. Sites of infection vary according to geographical location, the organism involved, and environmental and cultural differences. Both Tinea corporis, also referred to as 'ringworm' and Tinea cruris or 'jock itch' are conditions frequently seen by primary care doctors and dermatologists. The diagnosis can be made on clinical appearance and can be confirmed by microscopy or culture. A wide range of topical antifungal drugs are used to treat these superficial dermatomycoses, but it is unclear which are the most effective. Objectives To assess the effects of topical antifungal treatments in Tinea cruris and Tinea corporis. Search methods We searched the following databases up to 13th August 2013: the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library (2013, Issue 7), MEDLINE (from 1946), EMBASE (from 1974), and LILACS (from 1982). We also searched five trials registers, and checked the reference lists of included and excluded studies for further references to relevant randomised controlled trials. We handsearched the journal Mycoses from 1957 to 1990. Selection criteria Randomised controlled trials in people with proven dermatophyte infection of the body (Tinea corporis) or groin (Tinea cruris). Data collection and analysis Two review authors independently carried out study selection, data extraction, assessment of risk of bias, and analyses. Main results Of the 364 records identified, 129 studies with 18,086 participants met the inclusion criteria. Half of the studies were judged at high risk of bias with the remainder judged at unclear risk. A wide range of different comparisons were evaluated across the 129 studies, 92 in total, with azoles accounting for the majority of the interventions. Treatment duration varied from one week to two months, but in most studies this was two to four weeks. The length of follow-up varied from one week to six months. Sixty-three studies contained no usable or retrievable data mainly due to the lack of separate data for different Tinea infections. Mycological and clinical cure were assessed in the majority of studies, along with adverse effects. Less than half of the studies assessed disease relapse, and hardly any of them assessed duration until clinical cure, or participant-judged cure. The quality of the body of evidence was rated as low to very low for the different outcomes. Data for several outcomes for two individual treatments were pooled. Across five studies, significantly higher clinical cure rates were seen in participants treated with terbinafine compared to placebo (risk ratio (RR) 4.51, 95% confidence interval (CI) 3.10 to 6.56, number needed to treat (NNT) 3, 95% CI 2 to 4). The quality of evidence for this outcome was rated as low. Data for mycological cure for terbinafine could not be pooled due to substantial heterogeneity. Mycological cure rates favoured naftifine 1% compared to placebo across three studies (RR 2.38, 95% CI 1.80 to 3.14, NNT 3, 95% CI 2 to 4) with the quality of evidence rated as low. In one study, naftifine 1% was more effective than placebo in achieving clinical cure (RR 2.42, 95% CI 1.41 to 4.16, NNT 3, 95% CI 2 to 5) with the quality of evidence rated as low. Across two studies, mycological cure rates favoured clotrimazole 1% compared to placebo (RR 2.87, 95% CI 2.28 to 3.62, NNT 2, 95% CI 2 to 3). Data for several outcomes were pooled for three comparisons between different classes of treatment. There was no difference in mycological cure between azoles and benzylamines (RR 1.01, 95% CI 0.94 to 1.07). The quality of the evidence was rated as low for this comparison. Substantial heterogeneity precluded the pooling of data for mycological and clinical cure when comparing azoles and allylamines. Azoles were slightly less effective in achieving clinical cure compared to azole and steroid combination creams immediately at the end of treatment (RR 0.67, 95% CI 0.53 to 0.84, NNT 6, 95% CI 5 to 13), but there was no difference in mycological cure rate (RR 0.99, 95% CI 0.93 to 1.05). The quality of evidence for these two outcomes was rated as low for mycological cure and very low for clinical cure. All of the treatments that were examined appeared to be effective, but most comparisons were evaluated in single studies. There was no evidence for a difference in cure rates between Tinea cruris and Tinea corporis. Adverse effects were minimal - mainly irritation and burning; results were generally imprecise between active interventions and placebo, and between different classes of treatment. Authors' conclusions The pooled data suggest that the individual treatments terbinafine and naftifine are effective. Adverse effects were generally mild and reported infrequently. A substantial number of the studies were more than 20 years old and of unclear or high risk of bias; there is however, some evidence that other topical antifungal treatments also provide similar clinical and mycological cure rates, particularly azoles although most were evaluated in single studies.There is insufficient evidence to determine if Whitfield’s ointment, a widely used agent is effective. Although combinations of topical steroids and antifungals are not currently recommended in any clinical guidelines, relevant studies included in this review reported higher clinical cure rates with similar mycological cure rates at the end of treatment, but the quality of evidence for these outcomes was rated very low due to imprecision, indirectness and risk of bias. There was insufficient evidence to confidently assess relapse rates in the individual or combination treatments. Although there was little difference between different classes of treatment in achieving cure, some interventions may be more appealing as they require fewer applications and a shorter duration of treatment. Further, high quality, adequately powered trials focusing on patient-centred outcomes, such as patient satisfaction with treatment should be considered.

Paul Little - One of the best experts on this subject based on the ideXlab platform.

  • topical antifungal treatments for Tinea cruris and Tinea corporis
    Cochrane Database of Systematic Reviews, 2014
    Co-Authors: Magdy Elgohary, Hana Burgess, Liz Doney, Beth Stuart, Michael Moore, Esther J Van Zuuren, Zbys Fedorowicz, Paul Little
    Abstract:

    Background Tinea infections are fungal infections of the skin caused by dermatophytes. It is estimated that 10% to 20% of the world population is affected by fungal skin infections. Sites of infection vary according to geographical location, the organism involved, and environmental and cultural differences. Both Tinea corporis, also referred to as 'ringworm' and Tinea cruris or 'jock itch' are conditions frequently seen by primary care doctors and dermatologists. The diagnosis can be made on clinical appearance and can be confirmed by microscopy or culture. A wide range of topical antifungal drugs are used to treat these superficial dermatomycoses, but it is unclear which are the most effective. Objectives To assess the effects of topical antifungal treatments in Tinea cruris and Tinea corporis. Search methods We searched the following databases up to 13th August 2013: the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library (2013, Issue 7), MEDLINE (from 1946), EMBASE (from 1974), and LILACS (from 1982). We also searched five trials registers, and checked the reference lists of included and excluded studies for further references to relevant randomised controlled trials. We handsearched the journal Mycoses from 1957 to 1990. Selection criteria Randomised controlled trials in people with proven dermatophyte infection of the body (Tinea corporis) or groin (Tinea cruris). Data collection and analysis Two review authors independently carried out study selection, data extraction, assessment of risk of bias, and analyses. Main results Of the 364 records identified, 129 studies with 18,086 participants met the inclusion criteria. Half of the studies were judged at high risk of bias with the remainder judged at unclear risk. A wide range of different comparisons were evaluated across the 129 studies, 92 in total, with azoles accounting for the majority of the interventions. Treatment duration varied from one week to two months, but in most studies this was two to four weeks. The length of follow-up varied from one week to six months. Sixty-three studies contained no usable or retrievable data mainly due to the lack of separate data for different Tinea infections. Mycological and clinical cure were assessed in the majority of studies, along with adverse effects. Less than half of the studies assessed disease relapse, and hardly any of them assessed duration until clinical cure, or participant-judged cure. The quality of the body of evidence was rated as low to very low for the different outcomes. Data for several outcomes for two individual treatments were pooled. Across five studies, significantly higher clinical cure rates were seen in participants treated with terbinafine compared to placebo (risk ratio (RR) 4.51, 95% confidence interval (CI) 3.10 to 6.56, number needed to treat (NNT) 3, 95% CI 2 to 4). The quality of evidence for this outcome was rated as low. Data for mycological cure for terbinafine could not be pooled due to substantial heterogeneity. Mycological cure rates favoured naftifine 1% compared to placebo across three studies (RR 2.38, 95% CI 1.80 to 3.14, NNT 3, 95% CI 2 to 4) with the quality of evidence rated as low. In one study, naftifine 1% was more effective than placebo in achieving clinical cure (RR 2.42, 95% CI 1.41 to 4.16, NNT 3, 95% CI 2 to 5) with the quality of evidence rated as low. Across two studies, mycological cure rates favoured clotrimazole 1% compared to placebo (RR 2.87, 95% CI 2.28 to 3.62, NNT 2, 95% CI 2 to 3). Data for several outcomes were pooled for three comparisons between different classes of treatment. There was no difference in mycological cure between azoles and benzylamines (RR 1.01, 95% CI 0.94 to 1.07). The quality of the evidence was rated as low for this comparison. Substantial heterogeneity precluded the pooling of data for mycological and clinical cure when comparing azoles and allylamines. Azoles were slightly less effective in achieving clinical cure compared to azole and steroid combination creams immediately at the end of treatment (RR 0.67, 95% CI 0.53 to 0.84, NNT 6, 95% CI 5 to 13), but there was no difference in mycological cure rate (RR 0.99, 95% CI 0.93 to 1.05). The quality of evidence for these two outcomes was rated as low for mycological cure and very low for clinical cure. All of the treatments that were examined appeared to be effective, but most comparisons were evaluated in single studies. There was no evidence for a difference in cure rates between Tinea cruris and Tinea corporis. Adverse effects were minimal - mainly irritation and burning; results were generally imprecise between active interventions and placebo, and between different classes of treatment. Authors' conclusions The pooled data suggest that the individual treatments terbinafine and naftifine are effective. Adverse effects were generally mild and reported infrequently. A substantial number of the studies were more than 20 years old and of unclear or high risk of bias; there is however, some evidence that other topical antifungal treatments also provide similar clinical and mycological cure rates, particularly azoles although most were evaluated in single studies.There is insufficient evidence to determine if Whitfield’s ointment, a widely used agent is effective. Although combinations of topical steroids and antifungals are not currently recommended in any clinical guidelines, relevant studies included in this review reported higher clinical cure rates with similar mycological cure rates at the end of treatment, but the quality of evidence for these outcomes was rated very low due to imprecision, indirectness and risk of bias. There was insufficient evidence to confidently assess relapse rates in the individual or combination treatments. Although there was little difference between different classes of treatment in achieving cure, some interventions may be more appealing as they require fewer applications and a shorter duration of treatment. Further, high quality, adequately powered trials focusing on patient-centred outcomes, such as patient satisfaction with treatment should be considered.

  • Topical antifungal treatments for Tinea cruris and Tinea corporis (Protocol)
    Cochrane Database of Systematic Reviews, 2012
    Co-Authors: Magdy El-gohary, Hana Burgess, Liz Doney, Peter Hearn, Beth Stuart, Michael Moore, Elizabeth Johnson, Paul Little
    Abstract:

    To assess the effects of topical antifungal treatments and whether combination products, e.g. those containing topical corticosteroids plus antifungals, are any better than topical antifungals alone for treating Tinea corporis and Tinea cruris infections in men and women.

Owdi Prase - One of the best experts on this subject based on the ideXlab platform.

  • UJI KOMPARATIF PEMAKAIAN KRIM BUTENAFINE — I1C11% DENGAN KRIM KETOKONASOL NITRAT 2% PADA PENDERITA Tinea KRURIS (Studi Di Pondok Pesantren Toriqoh Kyai Ageng Giri Kusuma Mranggen Demak)
    2001
    Co-Authors: Owdi Prase
    Abstract:

    There are many variations reported for antifungal drugs. Ketoconazole has been used commonly as an ant fungal drug including Tinea cruris. Butenafine, a new antifungal drug is a benzylamine derivative which suppress the biosynthesis of ergosterol at an earl er stage of the metabolite pathway than ketoconazole. This study compared the effectiveness of butenafine hydrochloride 1 % cream and ketoconazole nitrat 2 % cream when used to treat Tinea cruris. Thirty five patients with Tinea cruris and positive potassium hydroxide examination and mycologic culture were done to determine the aetiologic agent, were divided in two group, in a double blind randomized controlled trial. The butenafine group consisted of 18 patients, and 17 patients in the ketoconazole group. Of the 35 patients assessed for effectiveness, side effect and clinical improvement applied once daily for a period of 2 weeks and 4 weeks after the end of treatment. Patients in the butenafine group had a higher percentage clinical improvement by day 7 (44.4 % vs 29.4 % p > 0.05), day 14 (72.3 % vs 58.8 % p 0.05) and day 42 which 4 weeks after the end of treatment (84.3 % vs 64.8 %, p > 0.05), but no significance different than the ketoconazole group. Adverse effect definitely related to butenafine were limited to one case of mild irritation sensation after application. Butenafine hydrochloride given for 2 weeks is effective in treating Tinea cruris. The proportion of clinical improvement increased at the day 7, day 14 and day 42. Banyak variasi yang dilaporkan dalarn obat-obat anti jamur. Anti jamur Ketokonasol lazirn digunakan sebagai obat anti jamur untuk Tinea kruris. Buitenafine suatu anti jamur baru, merupakan turunan benzilarnine menghambat biosintesis ergosterol pada stadium yang lebih awal clan pada ketokonasol. Penelitian ini membandingkan efektivitas butenafine hidroklorid 1% dengan ketokonasol nitrat 2% pada pengobatan Tinea kruris. Tiga puluh lima pasien dengan Tinea kruris dan pada pemeriksaan KOH positif dibagi dalam dua kelompok, secara acak terkontrol buta ganda. Kelompok butenafine terdiri dari 18 pasien, sedangkan kelompok ketokonasol 17 pasien. Pemeriksaan kultur dilakukan untuk menentukan etiologi spesies. Dari 35 pasien tersebut dinilai efektivitas, efek samping dan perbaikan klinik yang terjadi setelah pemberian selama 14 hari yang dioleskan sekali sehari. Kelompok butenafine menunjukkan prosentase perbaikan klinik yang lebih tinggi dibanding kelompok ketokonasol, H7(44.4% vs 29.4% dengan p > 0.05), H14 (72.3% vs 58.8% dengan p > 0.05) dan H42 (83.3% vs, 64.8% dengan p > 0.05), tetapi secara statistik tidak ada perbedaan yang berrnakna. Efek samping hanya dijumpai pada satu kasus dari kelompok butenafine berupa iritasi ringan. Butenafine yang diberikan selarna 2 minggu efektif untuk pengobatan Tinea kruris. Proporsi perbaikan klinik rneningkat prosentasenya pada hari ke 7, 14 dan 42

Prase Owdi - One of the best experts on this subject based on the ideXlab platform.

  • uji komparatifpemakaian krim butenafine i1c11 dengan krim ketokonasol nitrat 2 pada penderita Tinea kruris studi di pondok pesantren toriqoh kyai ageng giri kusuma mranggen demak
    2001
    Co-Authors: Prase Owdi
    Abstract:

    There are many variations reported for antifungal drugs. Ketoconazole has been used commonly as an ant fungal drug including Tinea cruris. Butenafine, a new antifungal drug is a benzylamine derivative which suppress the biosynthesis of ergosterol at an earl er stage of the metabolite pathway than ketoconazole. This study compared the effectiveness of butenafine hydrochloride 1 % cream and ketoconazole nitrat 2 % cream when used to treat Tinea cruris. Thirty five patients with Tinea cruris and positive potassium hydroxide examination and mycologic culture were done to determine the aetiologic agent, were divided in two group, in a double blind randomized controlled trial. The butenafine group consisted of 18 patients, and 17 patients in the ketoconazole group. Of the 35 patients assessed for effectiveness, side effect and clinical improvement applied once daily for a period of 2 weeks and 4 weeks after the end of treatment. Patients in the butenafine group had a higher percentage clinical improvement by day 7 (44.4 % vs 29.4 % p > 0.05), day 14 (72.3 % vs 58.8 % p 0.05) and day 42 which 4 weeks after the end of treatment (84.3 % vs 64.8 %, p > 0.05), but no significance different than the ketoconazole group. Adverse effect definitely related to butenafine were limited to one case of mild irritation sensation after application. Butenafine hydrochloride given for 2 weeks is effective in treating Tinea cruris. The proportion of clinical improvement increased at the day 7, day 14 and day 42. Banyak variasi yang dilaporkan dalarn obat-obat anti jamur. Anti jamur Ketokonasol lazirn digunakan sebagai obat anti jamur untuk Tinea kruris. Buitenafine suatu anti jamur baru, merupakan turunan benzilarnine menghambat biosintesis ergosterol pada stadium yang lebih awal clan pada ketokonasol. Penelitian ini membandingkan efektivitas butenafine hidroklorid 1% dengan ketokonasol nitrat 2% pada pengobatan Tinea kruris. Tiga puluh lima pasien dengan Tinea kruris dan pada pemeriksaan KOH positif dibagi dalam dua kelompok, secara acak terkontrol buta ganda. Kelompok butenafine terdiri dari 18 pasien, sedangkan kelompok ketokonasol 17 pasien. Pemeriksaan kultur dilakukan untuk menentukan etiologi spesies. Dari 35 pasien tersebut dinilai efektivitas, efek samping dan perbaikan klinik yang terjadi setelah pemberian selama 14 hari yang dioleskan sekali sehari. Kelompok butenafine menunjukkan prosentase perbaikan klinik yang lebih tinggi dibanding kelompok ketokonasol, H7(44.4% vs 29.4% dengan p > 0.05), H14 (72.3% vs 58.8% dengan p > 0.05) dan H42 (83.3% vs, 64.8% dengan p > 0.05), tetapi secara statistik tidak ada perbedaan yang berrnakna. Efek samping hanya dijumpai pada satu kasus dari kelompok butenafine berupa iritasi ringan. Butenafine yang diberikan selarna 2 minggu efektif untuk pengobatan Tinea kruris. Proporsi perbaikan klinik rneningkat prosentasenya pada hari ke 7, 14 dan 42.